BioCatalyst

Durvalumab, Oleclumab, Monalizumab — catalyst calendar

1 verified catalyst event(s) referencing Durvalumab, Oleclumab, Monalizumab, each linked to its official source. Verified as of 2026-06-22.

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-09-30
in 3mo
ESTIMATED
 READOUT
A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab
Phase 3 · Non-Small Cell Lung Cancer
 AZN ASTRAZENECA PLC Durvalumab, Oleclumab, Monalizumab ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.